TITLE

Recovery Studies on Metformin Hydrochloride and Gliclazide Combined Dosage Form (Tablets) Using Rp-Hplc Techniques

AUTHOR(S)
Saha, Dibyajyoti; Paul, Swati
PUB. DATE
December 2012
SOURCE
International Journal of Pharmacy Teaching & Practices (IJPTP);Dec2012, Vol. 3 Issue 4, p405
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Metformin hydrochloride is 1, 1-dimethyl biguanide hydrochloride and is also a hypoglecaemic drug. Gliclazide, is a third generation sulphonyl urea class hypoglycaemic drug which acts via stimulating β- cells of the isleta of langerhans of pancreas to release insulin. Metformin HCL differs markedly from glicazide and do not stimulate pancreatic β- cells but improve lipid profile well in type 2 diabetes.The research pathways were aimed at carrying out recovery studies of metformin hydrochloride and glicazide in combined dosage form (tablets) using RP-HPLC Techniques.
ACCESSION #
91569025

 

Related Articles

  • Metformin Best for Diabetic Patients With Heart Failure.  // Clinician Reviews;Oct2007, Vol. 17 Issue 10, p14 

    The article discusses research being done on antidiabetic agents for patients with heart failure. It references a study by Eurich D.T., McAlister F.A., Blackburn D.F., et al. in the 2007 issue of the "British Medical Journal". Metformin was confirmed to be the only antidiabetic agent, among...

  • hypoglycaemic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p292 

    The article presents information on hypoglycemic drugs. These drugs reduce the levels of glucose in the bloodstream. They are used mainly in the treatment of diabetes mellitus. The oral hypoglycemic drugs are primarily used to treat Type II diabetes mellitus, for example, the sulphonylurea...

  • Development and validation of UV spectrophotometric method for the determination of Gliclazide in tablet dosage form. Jamadar, Samina A.; Mulye, Snehal P.; Karekar, Poonam S.; Pore, Yogesh V.; Burade, Kishor B. // Der Pharma Chemica;2011, Vol. 3 Issue 4, p338 

    The article describes a simple, sensitive, rapid, accurate and precise spectrophotometric method for the estimation of gliclazide in bulk and pharmaceutical dosage forms. The wavelength maxima for gliclazide was found to be 229.5 nm with molar absorptivity of 1.4962x104l/mol/cm. Beer's law was...

  • ANTIDIABETIC ACTIVITY OF NIGELLA SATIVA L. SEED POWDER AND ITS COMBINATION WITH GLICLAZIDE IN ALLOXAN INDUCED DIABETIC MICE. ADNYANA, I. K.; SIGIT, J. I.; ASAD, S. A. // International Journal of Pharmacy & Pharmaceutical Sciences;2014, Vol. 6 Issue 10, p434 

    Objective: In Indonesia, Nigella sativa (NS) has been widely used for the treatment of diabetes mellitus. The aim of this study was to evaluate the antidiabetic activity of its seed powder and its combination with gliclazide. Methods: NS was used in seed powder suspension form. At study's begin,...

  • Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. Bodmer, Michael; Meier, Christian; Krahenbuhl, Stephan; Jick, Susan S.; Meier, Christoph R. // Diabetes Care;Nov2008, Vol. 31 Issue 11, p2086 

    OBJECTIVE -- Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs. RESEARCH DESIGN AND...

  • Haemodynamic and Metabolic Effects of Low Daily Dose Sulphonylureas in Diabetic Dog Hearts. Posa, Ildiko; Kocsis, Erzsebet; Nieszner, Eva; Pogatsa, Gabor; Koltai, Maria Zsofia // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jul2002, Vol. 52 Issue 7, p552 

    The effects of glibenclamide (GB, CAS 10238-21-8) and those of the latest low dally dose sulphonylurea compound, glimepiride (GM, CAS 93479-97-1) on myocardial haemodynamics and pyruvatelactate metabolism of healthy and alloxan-diabetic dogs (n = 6 in six groups) were compared. Mean arterial...

  • The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjects. Yudkin, J. S.; Panahloo, A.; Stehouwer, C.; Emeis, J. J.; Bulmer, K.; Mohamed-Ali, V.; Denver, A. E. // Diabetologia;Sep2000, Vol. 43 Issue 9, p1099 

    Aims/hypothesis. Improved glycaemic control might reduce both microvascular and macrovascular complications of Type II diabetes (non-insulin-dependent) mellitus. To explore such possible mechanisms, we investigated the effects of intensive treatment on markers of endothelial dysfunction and of...

  • Reduced second phase insulin secretion in carriers of a sulphonylurea receptor gene variant associating with Type II diabetes mellitus. ’t Hart, L. M.; Dekker, J. M.; van Haeften, T. W.; Ruige, J. B.; Stehouwer, C. D. A.; Erkelens, D. W.; Heine, R. J.; Maassen, J. A. // Diabetologia;Apr2000, Vol. 43 Issue 4, p515 

    Aims/hypothesis. The sulphonylurea receptor is a subunit of the ATP-sensitive potassium channel in the pancreatic beta cell. Mutations at nt –3 of the splice acceptor site of exon 16 and a silent mutation in exon 18 of the gene for the sulphonylurea receptor (SUR1) associate with Type II...

  • The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. Rendell, Marc // Drugs;2004, Vol. 64 Issue 12, p1339 

    The sulphonylureas act by triggering insulin release from the pancreatic β cell. A specific site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas leading to closure of the potassium channels and subsequent opening of calcium channels. This results...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics